Form 4: TENAX THERAPEUTICS Director Robyn Hunter Reports Acquisition of 80,000 Stock Options

TENAX THERAPEUTICS, INC. Director Robyn Hunter reported the acquisition of 80,000 stock options with an exercise price of $5.75, exercisable from July 1, 2026, and expiring on July 1, 2035.

Summary

• Robyn Hunter, a Director of TENAX THERAPEUTICS, INC. (TENX), reported changes in beneficial ownership of derivative securities.
• On July 1, 2025, Hunter acquired 80,000 stock options to buy common stock.
• These newly acquired options have an exercise price of $5.75 per share and were acquired at a price of $0.00, indicating a grant.
• The 80,000 options become exercisable on July 1, 2026, and expire on July 1, 2035.
• Following this transaction, Hunter directly beneficially owns 80,000 newly acquired stock options.
• Hunter also holds pre-existing stock options for 4 shares of common stock with an exercise price of $992, exercisable from June 9, 2023, and expiring on June 9, 2032.
• Additionally, Hunter holds pre-existing stock options for 100,000 shares of common stock with an exercise price of $5.94, exercisable from December 10, 2025, and expiring on December 10, 2034.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally a neutral to slightly positive signal, as it aligns the director's interests with the company's future stock performance. It's not a strong indicator of immediate financial health but suggests continued commitment.

Positives

• The acquisition of stock options by a director can signal confidence in the company's future performance and aligns their interests with shareholder value.
• The options were acquired at a $0.00 price, indicating they were likely granted as compensation, which is a common method to incentivize long-term commitment and performance.

Risks

• The value of the stock options is dependent on the future stock price of TENAX THERAPEUTICS, INC. exceeding the respective exercise prices.
• The options have specific expiration dates, meaning they will become worthless if not exercised before those dates.

Future Outlook

The document, an SEC Form 4, reports an insider transaction and does not provide explicit forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, which is a common practice in corporate governance across various industries, including biotechnology where Tenax Therapeutics operates. Such grants are typically used to align the interests of directors and executives with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The granting of stock options to directors is a standard practice in corporate governance across various industries, including biotechnology, to incentivize long-term performance and align interests with shareholders.
• The specific exercise prices ($5.75, $5.94) would typically be set at or above the market price on the grant date, which is common for incentive options. The $992 exercise price for 4 shares is unusual and might relate to a historical grant or stock split adjustment.
• The vesting schedule (exercisable one year after grant for the 80,000 options) is also a common industry practice to ensure continued service and performance.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the options gain value only if the stock price increases. This could be seen as a positive for long-term shareholder value.

Next Steps

• Monitor future Form 4 filings for additional insider transactions by Robyn Hunter or other TENAX THERAPEUTICS insiders.
• Observe TENAX THERAPEUTICS' stock performance relative to the option exercise prices to assess the potential value of these grants.

Key Dates

Keywords

TENAX THERAPEUTICS, TENX, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant, Robyn Hunter